Asthma (in children) - omalizumab (TA201) (replaced by TA278)
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11
This guidance has been replaced by TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
This guidance is about when omalizumab should be used to treat children aged 6 to 11 years with severe persistent allergic asthma in the NHS in England and Wales.
Asthma is a common condition that causes the airways to become narrower. Children with asthma have breathing difficulties, wheezing, coughing and feel a tightness in their chest. These symptoms get worse when they have an 'asthma attack'. Allergic asthma is caused by an allergy (for example, an allergy to pollen or dust mites). Children with severe persistent allergic asthma have frequent asthma attacks and often wake during the night because of their asthma.
What has NICE said?
NICE does not recommend omalizumab for children aged 6 to 11 years with severe persistent allergic asthma.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. Omalizumab does not provide enough benefit to children aged 6 to 11 years to justify its high cost.
- None found
This page was last updated: 19 April 2013
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.